Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3326
Timberland Bancorp
TSBK
$354M
| $1.1M | ﹤0.01% |
30,791
-175
| -0.6% | -$5.91K |
2022 Q3
13 quarters
|
|
3327
Nordic American Tanker
NAT
$1.78B
| $1.1M | ﹤0.01% |
319,820
+31,005
| +11% | +$110K |
2013 Q4
48 quarters
|
|
3328
PUT
Kinder Morgan
KMI
$69.2B
| $1.1M | ﹤0.01% |
40,000
| – | – |
2025 Q3
1 quarter
|
|
3329
Liquidity Services
LQDT
$1.35B
| $1.1M | ﹤0.01% |
36,262
+2,962
| +9% | +$79.6K |
2013 Q2
50 quarters
|
|
3330
Great Southern Bancorp
GSBC
$864M
| $1.09M | ﹤0.01% |
17,739
+5,124
| +41% | +$308K |
2016 Q3
37 quarters
|
|
|
KMTS
3331
Kestra Medical Technologies
KMTS
$1.63B
| $1.09M | ﹤0.01% |
41,170
+22,507
| +121% | +$580K |
2025 Q1
3 quarters
|
|
3332
Sweetgreen
SG
$1.08B
| $1.09M | ﹤0.01% |
161,412
-454,621
| -74% | -$3.12M |
2022 Q1
15 quarters
|
|
3333
CALL
Energy Fuels
UUUU
$2.84B
| $1.09M | ﹤0.01% |
75,000
| – | – |
2025 Q3
1 quarter
|
|
|
RWT
3334
Redwood Trust
RWT
$443M
| $1.09M | ﹤0.01% |
197,035
+8,115
| +4% | +$44.6K |
2013 Q2
50 quarters
|
|
3335
PUT
Stellantis
STLA
$12.8B
| $1.09M | ﹤0.01% |
100,000
-1,000,000
| -91% | -$10.8M |
2024 Q3
5 quarters
|
|
|
NPB
3336
Northpointe Bancshares
NPB
$531M
| $1.09M | ﹤0.01% |
64,780
+46,750
| +259% | +$791K |
2025 Q2
2 quarters
|
|
3337
PUT
YPF Sociedad Anonima ADS
YPF
$19.5B
| $1.08M | ﹤0.01% |
30,000
-30,000
| -50% | -$995K |
2025 Q3
1 quarter
|
|
3338
Corcept Therapeutics
CORT
$12.6B
| $1.08M | ﹤0.01% |
31,163
+18,182
| +140% | +$1.43M |
2016 Q2
38 quarters
|
|
|
YSG
3339
Yatsen Holding
YSG
$248M
| $1.08M | ﹤0.01% |
277,877
+115,057
| +71% | +$731K |
2022 Q1
15 quarters
|
|
|
HPP
3340
Hudson Pacific Properties
HPP
$623M
| $1.08M | ﹤0.01% |
99,690
+24,853
| +33% | +$369K |
2013 Q2
50 quarters
|
|
3341
World Acceptance Corp
WRLD
$813M
| $1.08M | ﹤0.01% |
7,677
+822
| +12% | +$124K |
2013 Q2
50 quarters
|
|
3342
Enliven Therapeutics
ELVN
$3.44B
| $1.08M | ﹤0.01% |
69,875
-814
| -1% | -$16.2K |
2023 Q1
11 quarters
|
|
|
VTYX
3343
DELISTED
Ventyx Biosciences
VTYX
| $1.07M | ﹤0.01% |
118,702
+116,876
| +6,401% | +$873K |
2022 Q1
15 quarters
|
|
|
ONTF
3344
DELISTED
ON24
ONTF
| $1.07M | ﹤0.01% |
134,266
-15,055
| -10% | -$85.3K |
2022 Q1
15 quarters
|
|
|
FSUN
3345
FirstSun Capital Bancorp
FSUN
$1.74B
| $1.07M | ﹤0.01% |
28,392
+9,275
| +49% | +$338K |
2024 Q4
4 quarters
|
|
3346
Invesco Mortgage Capital
IVR
$622M
| $1.07M | ﹤0.01% |
126,981
+31,165
| +33% | +$244K |
2013 Q2
50 quarters
|
|
3347
Insteel Industries
IIIN
$572M
| $1.07M | ﹤0.01% |
33,697
+5,324
| +19% | +$174K |
2016 Q1
39 quarters
|
|
3348
PUT
Invesco
IVZ
$13.5B
| $1.07M | ﹤0.01% |
+40,600
| New | +$992K |
2025 Q4
0 quarters
|
|
|
SFIX
3349
Stitch Fix
SFIX
$349M
| $1.07M | ﹤0.01% |
203,140
-185,342
| -48% | -$846K |
2017 Q4
32 quarters
|
|
3350
ATN International
ATNI
$430M
| $1.06M | ﹤0.01% |
46,678
+7,832
| +20% | +$145K |
2016 Q2
38 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.